Welcome to the Center of Infection and Immunity of Lille
From December 3th to 5th, 2018:
An International Symposium on BCG:
BCG 110 YEARS AFTER ITS CONCEPTION.
HERE for more details.
Friday December 14, 2018
Dr. Ales Berlec, Jožef Stefan Institute Department of Biotechnology, Slovenia: "Engineering lactic acid bacteria for therapy: some applications and tools", IBL auditorium 13h00
Tuesday December 18, 2018
Dr. Alvaro Baeza, Unité 1231 Inserm/Université de Bourgogne/Agrosup Dijon: "Plasmodium parasites : control of host immune responses by a conserved immunomodulator", Buttiaux IPL auditorium 13h00
Free course announcement
Infectious diseases are today still leading causes of global mortality and morbidity. One death out of four is due to infections, a proportion just behind cardiovascular diseases and twice as high as mortality due to cancer. This proportion is even higher in children, where infectious diseases are the first cause of death. In addition, the prevalence of chronic inflammatory and auto-immune diseases are on the rise, especially in the industrialized world. Therefore, the Center for Infection and Immunity of Lille is devoted to studying some of the most prevalent infectious disease, such as tuberculosis, malaria, hepatitis C, influenza, schistosomiasis, toxoplasmosis, pertussis, pneumococcal pneumonia, but also continuous threads, such as plague and several parasitic and viral diseases. These infections cannot be studied independently of their host environment, especially the immune system. Therefore, the second major area of research concerns the immune reaction against infections, and related immune dysfunctions of non-infectious diseases, such as allergic asthma and chronic obstructive pulmonary disease, which may be a leading cause of death by 2050. The objectives of the center are to gain deeper knowledge on the molecular and cellular mechanisms of these diseases and to apply this knowledge to the development of improved diagnostics, vaccines and therapeutics.
Camille LOCHT, Director
From another perspective
The European research program CHILD-INNOVAC, coordinated by Inserm, a license to develop an innovative, nasally administrable vaccine for the fight against whooping cough, which is experiencing a strong resurgence in the countries, has seen in recent years.
Its name is asthma, and it kills nearly 1500 people per year. This disease is characterized by a contraction of the bronchi, causing serious breathing difficulties. Although the origins of asthma are mainly allergy-related, we are starting to discover the impact of the environment on the development of asthma: air pollution is a factor, but common products, such as the plastic used in coating furniture, are being studied as well. Faced with these numerous challenges, Inserm researchers are studying various strategies to treat asthma. Interview with Anne Tsicopoulos, pulmonologist-allergist in Laboratory U1019 "Center for Infection & Immunity of Lille (CIIL).")".
Proteosomal degradation of NOD2 by NLRP12 in monocytespromotes bacterial tolerance and colonization by enteropathogen.
Nature Communications. 2019
Eur J Med Chem. 2019
The Regenerating Family Member 3 beta instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signaling for controlling colonization resistance independently of microbiota community structure.
PLoS Pathog. 2018
Nature Communications. 2018
SIGID LABORATORY : System Immunology and Genetics of Infectious Diseases
The Franco-Indian Laboratoire International Associé" System Immunology and Genetics of Infectious Diseases (LIA SIGID) is an open laboratory that has emerged from a long and fruitful collaboration between the teams of the laboratories of the CNRS that are linked to INSERM, Institut Pasteur de Lille, Lille University 2 and the Pierre and Marie Curie University in France and the teams of the Department of Biotechnology (DBT) with the TATA Institute for Fundamental Research (TIFR) as well is the SCB medical College and the ISPAT general hospital in India.
Federation Structure on Infectious, Inflammatory and Immune Diseases
The Center for Infection and Immunity of Lille and the research unit U995 constitute this structure that is supported by the University of Lille. The aim is to encourage research, networking, and training to boost discoveries in the field of Infections, Inflammatory and Immune-based diseases in Lille.
The CRB-EPLS (Centre de Recherche Biomédicale - Espoir Pour La Santé) is a Senegalese non-profit clinical research structure created in 1995 in Saint- Louis in Northern Senegal. This sub-saharian institution is attached to the CIIL as a clinical research field facility and is associated with the Institute Pasteur in Lille as part of the International Network of Pasteur Institutes. The activities of the CRB-EPLS are carried out by more than 40 employees on nearly 2000 m2 of premises. The Center has accessed to rural as well as urban areas in the Senegal River Basin and works in close collaboration with local health authorities. It focuses its investigations on major infectious diseases such as schistosomiasis, malaria or tuberculosis and the associated immune responses. The CRB-EPLS also carries out research on undernutrition among children and non-communicable chronic diseases such as hypertension, obesity and diabetes. CRB-EPLS is renowned for providing a high quality service for the management of clinical trials from Phase 1 to Phase 3 on public health issues specific to sub-Saharan countries.